Table 1.

Incidence of 48-hr survival and organ injury

	Anti-rabCD14		Anti-rabTNF		Controls
	Prophylactic treatment	Delayed treatment	Prophylactic treatment	Delayed treatment	LPS ± control mAb	No LPS
48-hr survival	100%*  (13/13)	100%*  (26/26)	100%*  (11/11)	67%  (8/12)	68%  (21/31)	100%*  (15/15)
Renal cortical necrosis	0%† (0/13)	0%† (0/26)	64% (7/11)	58% (7/12)	84% (26/31)	0%† (0/15)
Pulmonary injury	0%† (0/13)	0%† (0/26)	27% (3/11)	33% (4/12)	61% (19/31)	0%† (0/15)

^*P < 0.05 compared with untreated group (LPS ± control mAb) using Fisher Exact test. 

^†P < 0.001 compared with untreated group (LPS ± control mAb) using Fisher Exact test.